Postmenopausal Osteoporosis Drugs Market to Reach $17.6 Billion by 2035

Postmenopausal Osteoporosis Drugs market was valued at $11.4 billion in 2025 and is expected to reach $17.6 billion by 2035, registering a CAGR of 4.6% during the forecast period from 2026 to 2035. The market is expanding due to the increasing prevalence of osteoporosis among postmenopausal women, closely linked to global demographic aging and hormonal changes after menopause. As life expectancy rises, a larger proportion of women are living longer in postmenopausal stages, directly increasing the population at risk of fractures and bone density loss. This is translating into sustained demand for both preventive and therapeutic drug interventions, particularly long-term pharmacological treatments. Healthcare systems are also placing greater emphasis on fracture prevention to reduce hospitalization costs, further strengthening prescription volumes. In parallel, improved screening practices and guideline-based management are ensuring earlier diagnosis and continuous treatment adoption across key regions.

Browse the full report description of “Postmenopausal Osteoporosis Drugs Market Size, Share & Trends Analysis Report by Drug Class (Bisphosphonates, RANK Ligand (RANKL) Inhibitors, Selective Estrogen Receptor Modulators (SERMs), Parathyroid Hormone (PTH) Analogues, Sclerostin Inhibitors, Calcitonin, and Others), by Route of Administration (Oral, and Injectable), and by Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies), Forecast Period (2026-2035)” at https://www.omrglobal.com/industry-reports/postmenopausal-osteoporosis-drugs-market

Supporting this trend, recent data highlights the scale and urgency of the condition. According to the International Osteoporosis Foundation, over 200 million women globally are affected by osteoporosis, with postmenopausal women representing the majority of cases.

Key findings:

• Around 1 in 3 women over age 50 will experience osteoporotic fractures
• Osteoporosis causes over 8.9 million fractures annually worldwide
• Hip fractures are projected to increase by nearly 240% in women by 2050
• A significant proportion of patients remain undiagnosed or untreated, indicating unmet demand
• Aging population (65+) is growing rapidly, as highlighted by the United Nations, directly increasing the patient pool, UN World Population Ageing Report
• Postmenopausal bone loss accelerates within 5–10 years after menopause, driving early drug intervention.

Market Coverage

• The market number available for – 2025-2035
• Base year- 2025
• Forecast period- 2026-2035
• Segment Covered-
  • Drug Class
  • Route of Administration
  • Distribution Channel
• Regions Covered-
  • North America
  • Europe
  • Asia-Pacific
  • Rest of the World
• Competitive Landscape – Amgen Inc., Eli Lilly and Company, Merck & Co., Inc., Novartis AG, and Teva Pharmaceutical Industries Ltd., among others.

Key questions addressed by the report.

• What is the market growth rate?
• Which segment and region dominate the market in the base year?
• Which segment and region will project the fastest growth in the market?
• Who is the leader in the market?
• How are players addressing challenges to sustain growth?
• Where is the investment opportunity?

Global Postmenopausal Osteoporosis Drugs Market Report Segment

By Drug Class

• Bisphosphonates
• RANK Ligand (RANKL) Inhibitors
• Selective Estrogen Receptor Modulators (SERMs)
• Parathyroid Hormone (PTH) Analogues
• Sclerostin Inhibitors
• Calcitonin
• Others

By Route of Administration

• Oral
• Injectable

By Distribution Channel

• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies

Global Postmenopausal Osteoporosis Drugs Market Report Segment by Region

North America

• United States
• Canada

Europe

• UK
• Germany
• Italy
• Spain
• France
• Russia
• Rest of Europe

Asia-Pacific

• China
• India
• Japan
• South Korea
• Australia and New Zealand
• ASEAN Economies
• Rest of Asia-Pacific

Rest of the World

• Latin America
• Middle East & Africa

To learn more about this report request a sample copy @ https://www.omrglobal.com/request-sample/postmenopausal-osteoporosis-drugs-market